Connection
Edith Zemanick to Disease Progression
This is a "connection" page, showing publications Edith Zemanick has written about Disease Progression.
|
|
Connection Strength |
|
 |
|
 |
|
0.341 |
|
|
|
-
Hoppe JE, Wagner BD, Sagel SD, Accurso FJ, Zemanick ET. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis. BMC Pulm Med. 2017 Dec 11; 17(1):188.
Score: 0.085
-
Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, Gibson RL, Harris WT, Kurland G, Laguna TA, McColley SA, McCoy K, Retsch-Bogart G, Sobush KT, Zeitlin PL, Stevens MJ, Accurso FJ, Sagel SD, Harris JK. Airway microbiota across age and disease spectrum in cystic fibrosis. Eur Respir J. 2017 11; 50(5).
Score: 0.084
-
Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2012 Nov 01; 186(9):857-65.
Score: 0.059
-
Zemanick ET, Wagner BD, Harris JK, Wagener JS, Accurso FJ, Sagel SD. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. Pediatr Pulmonol. 2010 Jun; 45(6):569-77.
Score: 0.050
-
Zuckerman JB, Hinton AC, Lahiri T, Teneback CC, Jia S, Mermis J, Polineni D, Dasenbrook E, Sadeghi H, DiMango E, Dezube R, West NE, Zemanick ET, Samya ZN, Gifford AH. C-Reactive Protein Changes in Adult and Pediatric People With Cystic Fibrosis During Treatment of Pulmonary Exacerbations. Pediatr Pulmonol. 2025 Jan; 60(1):e27487.
Score: 0.035
-
Rice JD, Johnson RL, Juarez-Colunga E, Zemanick ET, Rosenfeld M, Wagner BD. Application of gap time analysis with flexible hazards to pulmonary exacerbations in the EPIC observational study. Biom J. 2022 08; 64(6):1075-1089.
Score: 0.029
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|